Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some cl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/371087 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850237699528589312 |
|---|---|
| author | Hui Fan Xuechun Lu Xiaohui Wang Yang Liu Bo Guo Yan Zhang Wenying Zhang Jing Nie Kaichao Feng Meixia Chen Yajing Zhang Yao Wang Fengxia Shi Xiaobing Fu Hongli Zhu Weidong Han |
| author_facet | Hui Fan Xuechun Lu Xiaohui Wang Yang Liu Bo Guo Yan Zhang Wenying Zhang Jing Nie Kaichao Feng Meixia Chen Yajing Zhang Yao Wang Fengxia Shi Xiaobing Fu Hongli Zhu Weidong Han |
| author_sort | Hui Fan |
| collection | DOAJ |
| description | Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some clinical benefits in patients with refractory advanced tumors; however, they are extremely toxic. Low doses of decitabine minimize toxicity while potentially improving the targeted effects of DNA hypomethylation. Based on these mechanisms, low-dose decitabine combined with chemoimmunotherapy may be a new treatment option for patients with refractory advanced tumors. We proposed the regimen of low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors. A favorable adverse event profile was observed in our trial that was highlighted by the finding that most of these adverse events were grades 1-2. Besides, the activity of our cohort was optimistic and the clinical benefit rate was up to 60%, and the median PFS was prolonged compared with PFS to previous treatment. We also identified a significant correlation between the PFS to previous treatment and clinical response. The low-dose DAC decitabine-based chemoimmunotherapy might be a promising protocol for improving the specificity and efficiency of patients with refractory advanced solid tumors. This trial is registered in the ClinicalTrials.gov database (identifier NCT01799083). |
| format | Article |
| id | doaj-art-1e18fa5c1e974fb2937753cd8a9e7243 |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-1e18fa5c1e974fb2937753cd8a9e72432025-08-20T02:01:40ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/371087371087Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II ReportHui Fan0Xuechun Lu1Xiaohui Wang2Yang Liu3Bo Guo4Yan Zhang5Wenying Zhang6Jing Nie7Kaichao Feng8Meixia Chen9Yajing Zhang10Yao Wang11Fengxia Shi12Xiaobing Fu13Hongli Zhu14Weidong Han15Department of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Geriatric Hematology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Immunology, Institute of Basic Medicine, Medical College of PLA, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Immunology, Institute of Basic Medicine, Medical College of PLA, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Geriatric Hematology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaDepartment of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, ChinaAberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some clinical benefits in patients with refractory advanced tumors; however, they are extremely toxic. Low doses of decitabine minimize toxicity while potentially improving the targeted effects of DNA hypomethylation. Based on these mechanisms, low-dose decitabine combined with chemoimmunotherapy may be a new treatment option for patients with refractory advanced tumors. We proposed the regimen of low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors. A favorable adverse event profile was observed in our trial that was highlighted by the finding that most of these adverse events were grades 1-2. Besides, the activity of our cohort was optimistic and the clinical benefit rate was up to 60%, and the median PFS was prolonged compared with PFS to previous treatment. We also identified a significant correlation between the PFS to previous treatment and clinical response. The low-dose DAC decitabine-based chemoimmunotherapy might be a promising protocol for improving the specificity and efficiency of patients with refractory advanced solid tumors. This trial is registered in the ClinicalTrials.gov database (identifier NCT01799083).http://dx.doi.org/10.1155/2014/371087 |
| spellingShingle | Hui Fan Xuechun Lu Xiaohui Wang Yang Liu Bo Guo Yan Zhang Wenying Zhang Jing Nie Kaichao Feng Meixia Chen Yajing Zhang Yao Wang Fengxia Shi Xiaobing Fu Hongli Zhu Weidong Han Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report Journal of Immunology Research |
| title | Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report |
| title_full | Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report |
| title_fullStr | Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report |
| title_full_unstemmed | Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report |
| title_short | Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report |
| title_sort | low dose decitabine based chemoimmunotherapy for patients with refractory advanced solid tumors a phase i ii report |
| url | http://dx.doi.org/10.1155/2014/371087 |
| work_keys_str_mv | AT huifan lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT xuechunlu lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT xiaohuiwang lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT yangliu lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT boguo lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT yanzhang lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT wenyingzhang lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT jingnie lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT kaichaofeng lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT meixiachen lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT yajingzhang lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT yaowang lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT fengxiashi lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT xiaobingfu lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT honglizhu lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport AT weidonghan lowdosedecitabinebasedchemoimmunotherapyforpatientswithrefractoryadvancedsolidtumorsaphaseiiireport |